Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in High CV Risk Hypercholesterolemia (ODYSSEY LONG TERM)
NCT01507831Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2012
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of alirocumab in hypercholesterolemia, sponsored by Sanofi. Started Jan 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01507831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01507831.